“…Similar to what has been observed in clinical settings, Plasmodium falciparum malaria parasites are able to acquire resistance under controlled laboratory conditions [16], [17], [18], [19], [20], [21], [22], [23], [24]. Although parasites exposed to potent antimalarials do not show protective, real-time transcriptional responses [25], the targets of novel antimalarials are often definitively revealed in in vitro selected resistant parasites through novel mutations or copy number variations in the parasite genome [20], [21], [22], [24], [26], [27], [28].…”